Abstract
Various methods for determining the expression of the β-galactosidase (β-gal) gene after retroviral transduction were compared as a means to assess retroviral titre. To allow better comparison, different retroviral vectors were constructed carrying two mutants of the green fluorescent protein and assessed as sensitive markers of retroviral gene transfer. It could be demonstrated that GFP is gener-ally superior to β-gal in terms of sensitivity, speed and noninvasiveness of assay, allowing easy direct FACS sorting of populations of transduced cells. This opens the possibility of enrichment by sorting of ex vivo transduced cells in gene therapy protocols.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Klein, D., Indraccolo, S., von Rombs, K. et al. Rapid identification of viable retrovirus-transduced cells using the green fluorescent protein as a marker. Gene Ther 4, 1256–1260 (1997). https://doi.org/10.1038/sj.gt.3300519
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3300519
Keywords
This article is cited by
-
Comparative evaluation of preclinical in vivo models for the assessment of replicating retroviral vectors for the treatment of glioblastoma
Journal of Neuro-Oncology (2011)
-
Gene therapy of ovarian cancer with IFN-α-producing fibroblasts: comparison of constitutive and inducible vectors
Gene Therapy (2006)
-
The murine whey acidic protein promoter directs expression to human mammary tumors after retroviral transduction
Cancer Gene Therapy (2002)
-
Differential effects of angiostatin, endostatin and interferon-α1 gene transfer on in vivo growth of human breast cancer cells
Gene Therapy (2002)
-
Accurate estimation of transduction efficiency necessitates a multiplex real-time PCR
Gene Therapy (2000)